MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-03-2026
Country |
 Israel |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
11.5 M |
Market Cap[1] |
$ 17.3 M |
EBITDA (LTM) |
$ -6.74 M |
P/E (LTM) |
-4.71 |
P/S (LTM) |
7.89 |
EPS (LTM) |
-0.31 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Aptorum Group Limited
APM
|
$ 1.06 | -0.93 % | $ 5.78 M | Nasdaq Global Select Market |  China |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.82 | -4.85 % | $ 464 M | Nasdaq Global Select Market |  Britain |
 |
Adagene
ADAG
|
$ 1.65 | - | $ 92.9 M | Nasdaq Global Market | China |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.45 | 3.6 % | $ 8.3 B | Nasdaq Capital Market |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 64.9 | -0.15 % | $ 8.68 B | Nasdaq Global Select Market,SPB |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Biogen
BIIB
|
$ 187.4 | 0.75 % | $ 27.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
BioXcel Therapeutics
BTAI
|
$ 1.98 | -1.0 % | $ 5.02 M | Nasdaq Global Select Market,SPB | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
CASI Pharmaceuticals
CASI
|
$ 1.04 | -2.34 % | $ 142 M | Nasdaq Capital Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Catalyst Biosciences
CBIO
|
$ 10.74 | -2.1 % | $ 707 M | Nasdaq Capital Market | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 23.58 | 2.39 % | $ 18.7 B | Nasdaq Global Select Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 27.0 | -1.28 % | $ 1.74 M | Nasdaq Global Select Market | USA |
 |
Cellectis S.A.
CLLS
|
$ 4.42 | -1.34 % | $ 116 M | Nasdaq Global Market | France |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Ascendis Pharma A/S
ASND
|
$ 201.94 | -3.26 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
BioVie
BIVI
|
$ 1.27 | -2.31 % | $ 1.88 M | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
BioNTech SE
BNTX
|
$ 99.81 | 0.97 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 27.75 | 0.02 % | $ 1.34 B | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 4.14 | -3.72 % | $ 9.01 B | NYSE American | Israel |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.13 | -2.02 % | $ 720 M | NYSE | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Axon Enterprise
AXON
|
$ 633.45 | 3.34 % | $ 48 B | Nasdaq Global Select Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Aytu BioScience
AYTU
|
$ 2.64 | -0.75 % | $ 16.6 M | Nasdaq Capital Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
AstraZeneca PLC
AZN
|
$ 94.65 | 0.68 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.